No Data
Esperion's (ESPR) Drugs Get EU Nod for Lowering Heart Risk
Esperion Therapeutics, Inc. ESPR and partner Daiichi Sankyo Europe GmbH announced that the European Commission (EC) has approved a label update for its drugs Nilemdo (bempedoic acid) and Nustendi for the treatment of hypercholesterolemia and to reduce the risk of adverse cardiovascular (CV) events.
Esperion to Participate in Upcoming June Investor Conferences
ANN ARBOR, Mich., May 23, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the following webcasted investor events during the month of May,
H.C. Wainwright Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $16
H.C. Wainwright analyst Joseph Pantginis maintains $Esperion Therapeutics(ESPR.US)$ with a buy rating, and maintains the target price at $16.According to TipRanks data, the analyst has a success rate
Esperion Therapeutics Inc: European Commission Approves Labeling Updates for Nilemdo and Nustendi
Esperion Therapeutics Inc: European Commission Approves Labeling Updates for Nilemdo and Nustendi
Express News | Esperion Therapeutics Inc: European Commission Approved Label Update of Both Nilemdo and Nustendi
First-In-Class Cholesterol-Lowering Treatment NILEMDO (NEXLETOL in the U.S.) and Its Combination With Ezetimibe, NUSTENDI (NEXLIZET in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk
– NILEMDO (bempedoic acid), a First-In-Class, Oral Treatment and NUSTENDI (bempedoic Acid / Ezetimibe Fixed-Dose Combination) Receive Label Update Approval from The European Commission as Treatments t